EGFR and non-small cell lung carcinoma: Previous clinical trials have shown the effectiveness of epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs) such as gefitinib, erlotinib, and afatinib, as a first‐line treatment for patients with EGFR‐mutated NSCLC.2, 3, 4, 5, 6, 7